Insulin-like growth factor-1 long arginine 3 (IGF-1 LR3) is a synthetic, altered version of the naturally occurring growth hormone insulin. Studies suggest that IGF-1 LR3 may be active up to 120 times longer than regular IGF-1 as it may have poor binding affinity for IGF-1 binding proteins. Research suggests the peptide’s activity may increase due to its reported longer half-life. It has been hypothesized that augmented cell proliferation and development, improved fat metabolism, and improved muscle repair and hypertrophy may result from IGF-1 LR3’s suppression of myostatin. Recent studies have suggested that IGF-1 LR3 may help nursing research models produce more breast milk.
IGF1-LR3 Peptide: What is it?
Insulin-like growth factor-1 has been tweaked to create IGF1-LR3. All Studies suggest that all IGF-1 analogs are crucial for cell growth, communication, and division. Although it appears to share IGF-1’s effects, IGF-1 LR3 is less likely to bind to IGF-binding proteins. Consequently, the half-life of IGF1-LR3 is 120 times that of IGF-1.
IGF-1 LR-3 and Cell Division
Studies suggest that IGF1-LR3 may promote cell growth and division similarly to IGF-1. It has been purported that muscle and bone may be the major targets, although they may also stimulate cell division in the liver, kidney, nerve, skin, lungs, and blood. Because it may encourage cell proliferation and differentiation, IGF-1 is purported to be responsible for cell maturation, which allows cells to perform their intended tasks. IGF1-LR3 has been speculated to activate cells at a rate about three times that of IGF-1 in the same quantities. It is important to remember that IGF1-LR3, like all other IGF-1 derivatives, may not stimulate cell growth (hypertrophy) but rather stimulate cell division and proliferation (hyperplasia), as research suggests. It has been proposed that IGF1-LR3 may not enhance the size of muscle cells but increase the number of muscle cells.
IGF-1 LR3 Peptide, Diabetes and Fat Metabolism
Studies suggest that when IGF-1R and insulin receptors are bound, IGF-1-LR3 may increase fat metabolism indirectly. Muscle, neuron, and liver cells are better able to take in glucose from the blood as a result of these measures. This lowers blood sugar levels, which causes the breakdown of glycogen and triglycerides in adipose tissue and the liver. This results in net energy consumption (net catabolism) and a net reduction in adipose tissue.
Scientists hypothesize that IGF1-LR3 may decrease endogenous insulin production and the need for insulin in diabetic research models, which makes sense given its potential involvement in lowering blood sugar. Research suggests this may often lead to a 10% reduction in insulin for maintaining stable blood sugar levels. This information might lead to new strategies for avoiding type 2 diabetes and reducing insulin requirements in research models with insulin resistance.
IGF-1 LR-3 Peptide and Myostatin
Myostatin, also known as growth differentiation factor 8, is a protein found in muscles believed to largely suppress the proliferation and specialization of skeletal muscle. Myostatin’s potential role in preventing unchecked muscle growth and promoting effective injury recovery is reportedly immense, yet there may be situations where blocking its activity might be beneficial.
Findings purport that myostatin inhibition may aid research models with Duchenne muscular dystrophy (DMD) or those with muscle atrophy due to lengthy periods of inactivity. Slowing muscle breakdown, maintaining strength, and avoiding morbidity may be possible by inhibiting this naturally occurring enzyme.
IGF1-LR3 and other IGF-1 derivatives have been suggested to protect muscle cells and inhibit apoptosis in Duchenne muscular dystrophy (DMD) animal models. MyoD activation suggests that IGF1- LR3’s extended half-life may contribute to its potency as a myostatin antagonist. Muscle growth is considered to be primarily triggered by the protein MyoD, often activated by activity or tissue injury.
IGF1-LR3 and Aging
Research suggests that through its potential in repairing and maintaining tissue, IGF1-LR3 may shield against cellular damage. Presenting animals with IGF1- LR3 has suggested promising results in slowing the aging process in bovines and swine. Mice are now being studied to see whether IGF1-LR3 may slow the development of various diseases and disorders, including dementia, muscular atrophy, and renal illness. IGF-1 has been speculated to improve health and lengthen the life of research models.
IGF-1 LR3 Peptide and Glucocorticoid Signaling
Glucocorticoids, largely released by the adrenal glands, play a significant role as agents in managing pain and inflammation caused by various conditions, including but not limited to cancer, neurological damage, and autoimmune disorders.
Core Peptides sells IGF1-LR3 only for use in academic and scientific studies; it is not intended for human use. Researchers can purchase Receptor Grade IGF1-LR3 through their online catalog.
